We are live on
!
Find out more
EC
EcoR1 Capital Portfolio holdings
AUM
$2.34B
1-Year Est. Return
204.53%
This Fund
S&P 500
This Quarter
Est. Return
+5.71%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$2.5B
AUM Growth
-$417M
(-14%)
Cap. Flow
-$110M
Cap. Flow
% of AUM
-4.41%
Top 10 Holdings %
Top 10 Hldgs %
69.34%
Holding
73
New
8
Increased
7
Reduced
9
Closed
16
Top Buys
| 1 |
Sarepta Therapeutics
SRPT
|
+$94.4M |
| 2 |
SWTX
SpringWorks Therapeutics
SWTX
|
+$54.5M |
| 3 |
uniQure
QURE
|
+$29.4M |
| 4 |
Zymeworks
ZYME
|
+$22.2M |
| 5 |
Xencor
XNCR
|
+$18.7M |
Top Sells
| 1 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$51.5M |
| 2 |
Viridian Therapeutics
VRDN
|
+$44.6M |
| 3 |
Nuvation Bio
NUVB
|
+$44M |
| 4 |
Vaxcyte
PCVX
|
+$40.3M |
| 5 |
Edgewise Therapeutics
EWTX
|
+$33.4M |
Sector Composition
| 1 | Healthcare | 99.86% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
APLS
1
DELISTED
Apellis Pharmaceuticals
APLS
| $379M | 15.16% |
11,890,843
| – | – |
|
|
2
Zymeworks
ZYME
$1.81B
| $220M | 8.79% |
15,028,079
+1,590,606
| +12% | +$22.2M |
|
3
Crinetics Pharmaceuticals
CRNX
$8.88B
| $219M | 8.76% |
4,288,120
| – | – |
|
4
Jazz Pharmaceuticals
JAZZ
$15.1B
| $210M | 8.39% |
1,706,469
| – | – |
|
5
Prothena Corp
PRTA
$450M
| $160M | 6.41% |
11,584,280
| – | – |
|
|
6
Xencor
XNCR
$1.11B
| $141M | 5.64% |
6,144,767
+814,351
| +15% | +$18.7M |
|
7
Arvinas
ARVN
$530M
| $129M | 5.15% |
6,726,491
| – | – |
|
8
AnaptysBio
ANAB
$1.67B
| $104M | 4.16% |
7,873,448
+78,452
| +1% | +$1.9M |
|
|
9
Sarepta Therapeutics
SRPT
$1.84B
| $93.6M | 3.74% |
+770,000
| New | +$94.4M |
|
10
Janux Therapeutics
JANX
$972M
| $78.7M | 3.14% |
1,469,818
| – | – |
|
|
11
uniQure
QURE
$2.8B
| $60M | 2.4% |
+3,400,000
| New | +$29.4M |
|
|
SWTX
12
DELISTED
SpringWorks Therapeutics
SWTX
| $56.4M | 2.25% |
+1,560,000
| New | +$54.5M |
|
13
CRISPR Therapeutics
CRSP
$4.99B
| $54.7M | 2.18% |
1,389,276
| – | – |
|
14
Immunome
IMNM
$2.56B
| $41.2M | 1.65% |
3,879,415
| – | – |
|
|
TECX
15
Tectonic Therapeutic
TECX
$613M
| $39.2M | 1.57% |
849,143
| – | – |
|
16
Tango Therapeutics
TNGX
$4.92B
| $32.8M | 1.31% |
10,630,736
-2,700,000
| -20% | -$12.5M |
|
|
THRD
17
DELISTED
Third Harmonic Bio
THRD
| $32.7M | 1.31% |
3,182,444
| – | – |
|
18
Kura Oncology
KURA
$1B
| $31M | 1.24% |
3,557,269
-2,249,602
| -39% | -$32.4M |
|
19
Neurogene
NGNE
$787M
| $29.1M | 1.16% |
1,271,342
| – | – |
|
20
Oric Pharmaceuticals
ORIC
$1.16B
| $27.6M | 1.1% |
3,418,068
| – | – |
|
21
Eton Pharmaceutcials
ETON
$1.05B
| $24.4M | 0.97% |
1,829,603
+1,263,528
| +223% | +$12.8M |
|
|
MBX
22
MBX Biosciences
MBX
$2.81B
| $23.2M | 0.93% |
1,259,273
+83,464
| +7% | +$1.78M |
|
23
Madrigal Pharmaceuticals
MDGL
$12.6B
| $23.1M | 0.92% |
75,000
| – | – |
|
24
Voyager Therapeutics
VYGR
$192M
| $22.2M | 0.89% |
3,917,546
| – | – |
|
25
Neumora Therapeutics
NMRA
$304M
| $22M | 0.88% |
2,071,450
| – | – |
|
Similar funds
G
MC
BAM
CC
HFM
NO
ST
MFAM